News for CytoDyn Inc. (CYDY)

CytoDyn (CYDY) unveiled a poster on leronlimab at the ESMO Breast Cancer Meeting 2025 in Munich, Germany. The presentation highlighted leronlimab's nove

**media[626992]**

VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CC

Robert E. Hoffman appointed as new CFO of CytoDyn (CYDY), effective May 15, 2025. Hoffman brings extensive financial leadership experience from roles at

Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in attendance VANCOUVER, Washingt

**media[608873]**

VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. (”œC

**media[569553]**

**media[548597]**

**media[494595]**

Incumbent Board's Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Inves

VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a C

**media[475548]**

Abstract to be presented at the 5th annual HIV Research for Prevention Conference Study results highlight potential for treatment VANCOUVER, Washington,...

CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

VANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (

VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or...

VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing...

VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (